23andMe (ME) Competitors $2.42 -0.32 (-11.68%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.52 +0.10 (+4.13%) As of 02/21/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ME vs. AVIR, TNGX, MNPR, SOPH, BNTC, ENGN, AMLX, URGN, AMRN, and BTMDShould you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Atea Pharmaceuticals (AVIR), Tango Therapeutics (TNGX), Monopar Therapeutics (MNPR), SOPHiA GENETICS (SOPH), Benitec Biopharma (BNTC), enGene (ENGN), Amylyx Pharmaceuticals (AMLX), UroGen Pharma (URGN), Amarin (AMRN), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. 23andMe vs. Atea Pharmaceuticals Tango Therapeutics Monopar Therapeutics SOPHiA GENETICS Benitec Biopharma enGene Amylyx Pharmaceuticals UroGen Pharma Amarin biote 23andMe (NASDAQ:ME) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment. Is ME or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Atea Pharmaceuticals' return on equity of -34.90% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets 23andMe-183.39% -170.07% -62.13% Atea Pharmaceuticals N/A -34.90%-32.38% Does the media refer more to ME or AVIR? In the previous week, 23andMe had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for 23andMe and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat 23andMe's score of -0.24 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 23andMe 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of ME or AVIR? 36.1% of 23andMe shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 26.3% of 23andMe shares are held by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate ME or AVIR? 23andMe currently has a consensus price target of $9.40, indicating a potential upside of 288.43%. Atea Pharmaceuticals has a consensus price target of $6.88, indicating a potential upside of 122.65%. Given 23andMe's higher probable upside, equities analysts clearly believe 23andMe is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 23andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ME or AVIR? Atea Pharmaceuticals received 6 more outperform votes than 23andMe when rated by MarketBeat users. However, 50.00% of users gave 23andMe an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperform23andMeOutperform Votes1250.00% Underperform Votes1250.00% Atea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Which has more risk and volatility, ME or AVIR? 23andMe has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Which has higher earnings and valuation, ME or AVIR? Atea Pharmaceuticals has lower revenue, but higher earnings than 23andMe. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio23andMe$219.64M0.30-$666.70M-$15.45-0.16Atea PharmaceuticalsN/AN/A-$135.96M-$2.07-1.49 SummaryAtea Pharmaceuticals beats 23andMe on 10 of the 17 factors compared between the two stocks. Get 23andMe News Delivered to You Automatically Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ME vs. The Competition Export to ExcelMetric23andMePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.93M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.166.1326.4618.82Price / Sales0.30312.32457.0180.82Price / Cash0.9267.8344.0437.47Price / Book1.036.747.634.64Net Income-$666.70M$138.11M$3.18B$245.69M7 Day Performance-5.10%-2.02%-1.82%-2.63%1 Month Performance-32.40%-1.54%0.22%-2.37%1 Year Performance-81.95%-3.14%17.49%13.65% 23andMe Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ME23andMe1.3628 of 5 stars$2.42-11.7%$9.40+288.4%-81.9%$73.51M$219.64M-0.16770Analyst ForecastNews CoverageAVIRAtea Pharmaceuticals2.743 of 5 stars$3.15+1.3%$6.88+118.4%-26.6%$266.05MN/A-1.5270TNGXTango Therapeutics3.4582 of 5 stars$2.47-1.6%$12.33+399.3%-78.7%$265.32M$43.38M-2.0990MNPRMonopar Therapeutics0.9201 of 5 stars$43.10-3.5%$43.00-0.2%+1,312.3%$262.91MN/A-21.8810SOPHSOPHiA GENETICS2.7365 of 5 stars$4.01+1.8%$7.40+84.5%-15.0%$262.15M$64.49M-3.68520BNTCBenitec Biopharma2.7665 of 5 stars$11.25+16.0%$24.43+117.1%+211.4%$261.23M$80,000.000.0020Earnings ReportAnalyst ForecastNews CoverageGap UpENGNenGene3.7685 of 5 stars$5.90-5.6%$26.44+348.2%-59.7%$260.90MN/A-10.1731Analyst ForecastAMLXAmylyx Pharmaceuticals2.5508 of 5 stars$3.72+3.6%$7.33+97.1%-78.4%$255.00M$196.49M-0.97200URGNUroGen Pharma3.833 of 5 stars$10.77+2.2%$43.70+305.8%-43.0%$252.56M$82.71M-3.42200Analyst ForecastNews CoverageAMRNAmarin0.3188 of 5 stars$0.61+1.2%N/A-49.4%$251.49M$306.91M-6.80360BTMDbiote3.3529 of 5 stars$4.58flat$10.00+118.3%-9.5%$248.86M$193.06M17.62194 Related Companies and Tools Related Companies AVIR Competitors TNGX Competitors MNPR Competitors SOPH Competitors BNTC Competitors ENGN Competitors AMLX Competitors URGN Competitors AMRN Competitors BTMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ME) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ME Stock Alerts